Heart Matters
Heart Matters is a medical education podcast from ReachMD designed for cardiology physicians. It covers essential strategies and research on cardiovascular disease, including coronary artery disease, heart attacks, high cholesterol, and high blood pressure. The series aims to help clinicians improve patient heart health and stay updated on the latest cardiology research.
Episodes
Examining the Link Between Surgical Menopause and Heart Failure
Guest: Elise Shalowitz, MS
New research is examining the relationship between gynecologic surgery and heart failure in women. Learn more about how surgery type and timing were associated with heart failure risk with Elise Shalowitz, a Principal Clinical Research Professional at the Colorado Center for Personalized Medicine at the University of Colorado Anschutz School of Medicine.
Navigating Chronic Anticoagulation Reversal in Cardiothoracic Surgery
Host: Brian P. McDonough, MD, FAAFP
Guest: Ahmet Kilic, MD FACS
When cardiothoracic surgery can’t wait, chronic anticoagulation can further complicate an already complex clinical picture. In this conversation with Dr. Brian McDonough, Dr. Ahmet Kilic explores the factors that can help inform anticoagulation reversal decisions in time-sensitive scenarios. Dr. Kilic is a Profes
Improving ATTR-CM Care Through Community-Specialist Partnership
Guest: Alex Reyentovich, MD
Community providers and amyloidosis specialists each play a vital role in diagnosing and managing transthyretin amyloid cardiomyopathy (ATTR-CM). Join Dr. Alex Reyentovich as he explains how this partnership can improve both patient care and diagnosis rates. Dr. Reyentovich is a Professor in the Department of Medicine at NYU Grossman School of Medicine and
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
Guest: M. Melih Dogan, MD
What does current evidence tell us about subcutaneous lipoprotein(a)-lowering therapies? Find out as Dr. M. Melih Dogan shares findings from a recent meta-analysis examining their efficacy, safety, and effects on key lipid parameters, along with the limitations that remain as larger clinical trials continue. He's a Postdoctoral Researcher at East Carolina Un
Exploring AI-Powered ATTR-CM Detection
Guest: Bruno Batinica, MD
Earlier recognition of ATTR-CM remains a challenge, but emerging applications of AI could offer a new way to raise clinical suspicion. Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, explores how AI models could identify patterns in ECG and echocardiography that may help flag patients for further evaluation.
Advancing ATTR-CM Identification: Early Findings from TRACE-AI
Guest: Bruno Batinica, MD
Could multimodal AI help identify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who might otherwise go undiagnosed? Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, joins us to share early findings from the TRACE-AI study, including AI-enabled model performance across diverse health systems, the potential value of c
Anticoagulation Reversal Decisions in Cardiothoracic Surgery: Case-Based Insights
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Akshay Kumar, MD
In cardiothoracic surgery, the need for anticoagulation reversal can arise quickly, and the path forward isn’t always clear. In this case-based discussion with Dr. Brian McDonough, Dr. Akshay Kumar shares his perspective on making anticoagulation reversal decisions across a range of urgent and complex surgi
Navigating ASCVD and Pancreatitis Risk in Severe Hypertriglyceridemia
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Freeman, MD, FACC, FACP
In this episode of Heart Matters, Dr. Charles Turck is joined by Dr. Andrew Freeman to take a case-based look at severe hypertriglyceridemia and explore how the 2026 American College of Cardiology/American Heart Association Multisociety guideline on dyslipidemia management can help inform clinical deci
A More Complete View of Cardiovascular Risk in Women
Guest: Noel Bairey Merz, MD
Cardiovascular risk in women can emerge well before older age, but traditional approaches to risk assessment may overlook sex-specific factors in patients under 65. Dr. Noel Bairey Merz joins us to share how tools such as the PREVENT score and coronary artery calcium scoring, along with obstetric history and female-dominant conditions, can help us identify
Updated AACE Guidance on Managing Dyslipidemia in T2D
Guest: Scott D. Isaacs, MD FACP, FACE
Dyslipidemia is a major driver of cardiovascular risk in patients with type 2 diabetes (T2D), and lipid management is a key component of the 2026 AACE diabetes algorithm. Join Dr. Scott Isaacs as he reviews new recommendations on LDL-C goals and individualized care in this population. Dr. Isaacs is the Immediate Past President of the American Ass
Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk
Guest: Scott D. Isaacs, MD FACP, FACE
For patients with diabetes, effective care requires more than just lowering A1C. Dr. Scott Isaacs joins us to discuss the importance of incorporating comorbidities into care and strategies for systematic screening and follow-up. He’s the Immediate Past President of the American Association of Clinical Endocrinology and an Associate Professor of M
Applying Guideline Recommendations to ACS Management
Host: Steve Jackson, PharmD
Guest: Sunil Rao, MD
The 2025 American College of Cardiology/American Heart Association Guideline for the Management of Patients With Acute Coronary Syndromes (ACS) reflects more than a decade of new evidence, but what will actually change at the bedside? Tune in to find out as Dr. Sunil Rao, Chair of the Joint Committee on Clinical Practice Guidelines
Overcoming Challenges in ATTR-CM Diagnosis
Guest: Sumeet Mitter MD, MSc, FACC
Even with advances in noninvasive imaging, diagnosing ATTR-CM isn’t always straightforward. That's why Dr. Sumeet Mitter joins us to discuss how we can address key challenges in diagnosis and navigate the path to treatment. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inov
Multidisciplinary Care in ATTR-CM: Building the Right Team
Guest: Sumeet Mitter MD, MSc, FACC
Because transthyretin amyloid cardiomyopathy (ATTR-CM) is a systemic disease, effective ATTR-CM management requires expertise beyond cardiology. Dr. Sumeet Mitter joins us to discuss the roles of neurology, hematology-oncology, genetic counseling, and nephrology in caring for these patients. He's the Director of Inova Schar Heart and Vascular Resear
Building Clinical Expertise in ATTR-CM Management
Guest: Sumeet Mitter MD, MSc, FACC
As advances in RNA silencers, gene-editing technologies, and immunotherapy reshape the ATTR-CM landscape, it's important to stay informed and build confidence navigating this increasingly complex field. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in
The Future of ATTR-CM Care: A Look at What's Next
Guest: Sumeet Mitter MD, MSc, FACC
The future of ATTR-CM care may extend beyond slowing disease progression to detecting it sooner—and potentially reversing its effects. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, explores emerging innovations that could open the door to
Managing Acute PE: Updates from the 2026 AHA/ACC Guideline
Host: Mary Leuchars, MD
Guest: Mark Creager, MD
The 2026 American College of Cardiology/American Heart Association Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults introduces a new clinical categorization framework to help evaluate risk and determine the appropriate care setting and treatment for patients with acute pulmonary embolism. Review key
From Goals to Action: Multisociety Guidance on Lipid Management
Guest: Ann Marie Navar, MD, PhD
With LDL cholesterol goals reinstated in the 2026 American College of Cardiology and American Heart Association Guideline on the Management of Dyslipidemia, we now have a clearer framework for intensifying lipid-lowering therapy. Dr. Ann Marie Navar explains how to select nonstatin therapies based on the degree of LDL lowering needed, patient preferenc
Managing Dyslipidemia: 2026 ACC/AHA Guideline Updates
Guest: Roger Blumenthal, MD
What do the 2026 American College of Cardiology (ACC) and American Heart Association (AHA) dyslipidemia guideline updates mean for patient care? Join Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, as he reviews key recommendations that can help us personalize cardiovascular risk reduction and improve long-term prevention. Dr. Blumenthal is
How PCSK9 Inhibition Lowers LDL Cholesterol
Guest: Ann Marie Navar, MD, PhD
How does PCSK9 inhibition lower LDL cholesterol? Find out as Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, explains the biology behind this therapeutic approach.
Enlicitide for LDL-C Management: Insights from CORALreef Lipids
Guest: Ann Marie Navar, MD, PhD
The CORALreef Lipids trial helped establish the clinical evidence supporting the FDA approval of enlicitide for LDL-C management. Join Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, for a discussion of the trial's efficacy, safety, and durability. She also explores key considerations for i
Risk Prediction with the PREVENT-ASCVD Equations
Guest: Roger Blumenthal, MD
As the drivers of cardiovascular disease have shifted over time, so have the tools used to estimate risk. Dr. Roger Blumenthal explains why the PREVENT-ASCVD equations represent an important advance over traditional models and what that means for more accurate, individualized preventive care. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology
The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Erin D. Michos, MD, MHS
Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a mo
Evaluating ASCVD Risk with the CPR Framework
Guest: Roger Blumenthal, MD
The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guid
Looking Ahead in ATTR-CM Care: Improving Diagnosis, Outcomes, and Equity
Guest: Frederick Ruberg, MD
What will the future of transthyretin amyloid cardiomyopathy (ATTR-CM) care look like? Dr. Frederick Ruberg joins us to share his perspective on the advances that may shape the next phase of patient care, from screening and therapeutic strategies to expanded genetic testing aimed at identifying patients earlier. He's the Chief of Cardiovascular Medicine at
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Host: Shelina Ramnarine, PhD
Guest: Payal Kohli, MD, FACC
In women, hypertension follows a distinct biological and clinical course that evolves across reproductive and menopausal transitions, but its long-term implications remain underrecognized and undertreated. In this expert-led discussion, Dr. Shelina Ramnarine and Dr. Payal Kohli examine key considerations in managing hypert
Early Recognition of ATTR-CM: Key Signs and Diagnostic Strategies
Guest: Valmiki Maharaj, MD
With increasing recognition and more accessible diagnostic tools, ATTR-CM can no longer be overlooked in patients with atypical heart failure presentations. Dr. Valmiki Maharaj shades insights on connecting clinical clues, confirming diagnosis efficiently, and acting earlier to meaningfully impact long-term outcomes. He's the Director of the Heart Fa
Diagnosing ATTR-CM: Recent Advances and Future Directions
Guest: Ronald Witteles, MD
Even with growing awareness of transthyretin amyloid cardiomyopathy (ATTR-CM), delays in diagnosis remain a significant challenge. That's why Dr. Ronald Witteles, Professor of Cardiovascular Medicine at Stanford Medicine and Co-Director of the Stanford Amyloid Center, joins us to share practical strategies for recognizing ATTR-CM, implementing the appropria
When to Suspect ATTR-CM: Clues for Earlier Diagnosis
Guest: Ronald Witteles, MD
What clinical clues should raise suspicion for transthyretin amyloid cardiomyopathy (ATTR-CM)? Find out as Dr. Ronald Witteles examines the cardiac and extracardiac manifestations that can help us recognize this often-overlooked disease. He's a Professor of Cardiovascular Medicine at Stanford Medicine and the Co-Director of the Stanford Amyloid Center and M
Understanding the Mechanisms Behind Resistant Hypertension
Host: Steve Jackson, PharmD
Guest: Jan Basile, MD
Guest: Michael J. Bloch, MD, FAHA, FASH, FNLA
When blood pressure remains uncontrolled despite treatment, adding more medications may not address the underlying cause. In this expert-led discussion, Drs. Jan Basile and Michael Bloch join Dr. Steve Jackson to examine often-overlooked drivers of hypertension, including aldostero
Quality of Life Conversations in ATTR-CM Care
Guest: Kevin S. Shah, MD
Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience significant quality of life challenges that extend beyond cardiac symptoms, including reduced mobility, fatigue, mood changes, and loss of independence. Dr. Kevin Shah discusses practical, patient-centered strategies to identify functional limitations, support emotional well-being,
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Host: Alexandria May, PharmD, BCPS
Guest: Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Hypertension is a key modifiable cardiovascular risk factor, but its prevalence, progression, and outcomes vary significantly across patient populations. In this program, Dr. Alexandria May and Dr. Keith Ferdinand discuss how social drivers of health, geography, access to care, and c
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
Host: Steve Jackson, PharmD
Guest: Robert H. Eckel, MD, FAHA, FACC, FNLA
Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that can severely disrupt triglyceride metabolism and place patients at risk for life-threatening complications like acute pancreatitis. Tune in to hear Dr. Robert Eckel in conversation with Dr. Steve Jackson as they break down the key cardio
Advances in Sports Cardiology: Updates from ACC 2026
Guest: Jeffrey Hsu, MD, PhD
The field of sports cardiology has experienced remarkable growth, with new guidelines, expanding programs, and increasing recognition of cardiovascular risk in athletes. Hear from Dr. Jeffrey Hsu as he shares current and emerging approaches to risk assessment, prevention, and management of cardiac conditions in this population. Dr. Hsu is a Clinical
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Guest: Joban Vaishnav, MD
For patients newly diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), it's essential to set realistic expectations and prioritize whole-person care. Dr. Joban Vaishnav, Assistant Professor of Medicine and Director of the Comprehensive Amyloidosis Center at Johns Hopkins Medicine, shares insights on guiding these patients through this diag
Counseling Patients on Disease Progression in ATTR-CM
Guest: Joban Vaishnav, MD
When transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, an individualized and empathetic approach to patient conversations is key. Hear from Dr. Joban Vaishnav as she shares practical strategies for addressing patient fears while clarifying what progression truly means. Dr. Vaishnav is an Assistant Professor of Medicine and Director of the Compre
AI-Driven Advances in ATTR-CM Care
Guest: Frederick Ruberg, MD
Artificial intelligence has rapidly advanced disease recognition in transthyretin amyloid cardiomyopathy (ATTR-CM), and its role in guiding treatment selection, predicting progression, and refining prognosis is now being explored. Discover what's next in ATTR-CM care with Dr. Frederick Ruberg, Chief of Cardiovascular Medicine at Boston Medical Center and T
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Guest: Ahmad Masri, MD, MS
New therapeutic approaches are reshaping how we think about managing transthyretin amyloidosis (ATTR). Gain insight into the next generation of ATTR therapies as Dr. Ahmad Masri highlights evolving strategies beyond traditional stabilizers. He's an Associate Professor of Medicine in the Division of Cardiovascular Medicine at Oregon Health and Science Univer
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Guest: Kevin Alexander
In the past decade, significant strides have been made in diagnosing and treating patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Increased disease awareness, non-invasive diagnostic tools like scintigraphy, and AI-assisted screening have led to earlier detection and improved outcomes. Learn more with Dr. Kevin Alexander, an Assistant Professor of
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Guest: Quan Bui, MD
Quality of life in transthyretin cardiac amyloidosis (ATTR-CM) varies widely by disease stage, but early detection and treatment can make a profound difference. Hear from Dr. Quan Bui as he highlights how recent therapeutic advances have transformed symptom management, even in advanced cases. Dr. Bui is a cardiologist and Assistant Professor of Medicine at
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Guest: Susan Davis
Emerging research is challenging long-held assumptions about the roles of estrogen and testosterone in women’s health—particularly in the context of aging and cardiometabolic risk. Hear from Dr. Susan Davis as she reviews the evolving evidence. Dr. Davis is an endocrinologist as well as the head of the Women’s Health Research Program and a Professor of Women's Heal
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
A recent study explored the emerging role of KCNQ5 potassium channels in vascular smooth muscle regulation and their potential as therapeutic targets to promote vasodilation and manage blood pressure. Hear from Dr. Geoffrey Abbott as he dives into cutting-edge research using a CRISPR-generated KCNQ5 knockout rat model, revealing critical insights into adrenergic signaling, vascular react
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Guest: Jun-ichi Abe, MD, PhD
Cancer therapies can trigger both acute and chronic vascular effects, from treatment-induced hypertension to long-term atherosclerotic changes. Learn more as Dr. Jun-ichi Abe shares insights from his presentation at the 2025 American Heart Association Scientific Sessions. Dr. Abe is a Professor in the Department of Cardiology at The University of Texas MD
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Understanding how lipids and lipoproteins are formed, metabolized, and cleared is essential for accurate lipid interpretation and cardiovascular risk assessment. Hear from Dr. Robert Eckel as he explains these molecular mechanisms and implications for patient management. Dr. Eckel is a Professor Emeritus of Medicine with a primary appointment in the Division of Endocrinology, Metabolism,
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Sex-based differences in lipid metabolism can have critical impacts on cardiovascular risk assessment and treatment. Hear from Dr. Connie Newman as she explains why understanding lipid metabolism in women is essential for accurate risk stratification and optimal treatment decisions. Dr. Newman is an Adjunct Professor in the Department of Medicine and the Holman Division of Endocrinology,
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Cardiovascular disease is the leading cause of mortality in women, yet it is often underrecognized due to gender bias in healthcare. Hear from Dr. Connie Newman as she explores the impact of bias on cardiovascular risk perception, highlights the importance of lipid and Lp(a) screening, and reviews evidence-based statin therapy strategies to improve outcomes for women. Dr. Newman is an Ad
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Effective lipid management depends on identifying how specific dietary factors drive LDL cholesterol and triglyceride elevations. Dr. Robert Eckel shares evidence-based strategies for tailoring nutrition recommendations in patients with hypercholesterolemia and hypertriglyceridemia. Dr. Eckel is a Professor Emeritus of Medicine with a primary appointment in the Division of Endocrinology,
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Statin intolerance, though uncommon, presents a challenge for patients who experience persistent side effects despite adjustments in dosing or switching statins. Dr. Matthew Sorrentino reviews evidence-baesd alternatives, shares insights on practical use in clinical care, and highlights the latest advances in lipoprotein (a)–targeted therapies now in late-stage development. Dr. Sorrentin
Improving Lipid Management Through Equity-Focused Clinical Strategies
Despite advances in lipid-lowering therapies, disparities in hyperlipidemia diagnosis and treatment persist. Dr. Keith Ferdinand examines how social drivers of health impact access, adherence, and outcomes and explains how clinicians can help address gaps in care for underserved populations. Dr. Ferdinand is a Professor of Medicine as well as the Gerald S. Berenson Chair in Preventative
Optimizing Cardiovascular Outcomes in Hyperlipidemia Through Risk-Based Care
Effective management of hyperlipidemia requires tailoring treatment to a patient’s cardiovascular risk profile. Lifestyle modification remains the cornerstone of care, while high-risk patients often require pharmacotherapy. Dr. Keith Ferdinand shares evidence-based strategies for reducing LDL and addressing comorbidities while engaging patients in shared decision making. Dr. Ferdinand is
How Artificial Sweeteners Could Be Linked to Heart Disease
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Wilson Tang, MD
Many different artificial sweeteners are being consumed by patients; however, this discussion will focus on research around one that has been used in the food industry for a long time, called erythritol. Interestingly, it was found that patients with cardiac problems had the highest levels of erythritol
Allergic Reactions and Cardiac Concerns: Exploring the Heart Disease Link
Host: Javed Butler, MD
Guest: Jeffrey Wilson, MD
There’s a decent amount of evidence showing allergic immune responses could have connections with heart disease. But with the knowledge gaps that exist, a need for bigger cohorts is necessary to get more information and data. So to explore the link between allergic reactions from food and heart disease, Dr. Javed Butler is joined b
Active Aging: Preventing Heart Failure in Older Women with Exercise
Host: Javed Butler, MD
Guest: Michael J. LaMonte, PhD, MPH
The American Heart Association recommends physical activity to help lower the risk of heart failure, but how much exercise is needed, especially for older women, to lower that risk? According to a recent study, even just low-intensity exercise for 30 minutes is associated with a 25 percent lower risk of overall heart fail
AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD
Host: Javed Butler, MD
Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S.
For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and
Pharmacist-Prescribing and Hypertension Management: An Economic Benefit
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Dave L. Dixon, PharmD, FACC, FCCP, FNLA, BCPS, BCACP, CDE, CLS
What would the cost-effectiveness look like if the uptake of a pharmacist-prescribing model for hypertension were to be put into practice? A new study shows that a pharmacist-prescribing method could have significant economic impact on the U.S. healthcare s
Improving Symptoms, Function, and Weight Loss in HFpEF Patients with Obesity
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Javed Butler, MD
There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here
A Discussion on Statins to Lower CVD Risk for HIV Patients
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD
The risk of cardiovascular disease is twice as great among patients living with HIV, and this could partly be due to traditional risk factors, along with nontraditional risk factors. Here to discuss the results from the REPRIEVE study with Dr. Mary Katherine Cheeley is Dr. Steve Grinspoon, Co-Princip
A Discussion on the Updated Recommendations for Managing Dyslipidemia in Adults
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA
The National Lipid Association (NLA) recently published updated recommendations for lifestyle therapies to manage three common dyslipidemias in adults. To discuss this, Dr. Mary Katherine Cheeley is joined by Dr. Carol Kirkpatrick, Clinical Lipid Specialist and Clinical Scient
Identifying Cardiovascular Risk Factors for HIV Patients
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD
Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and D
Exploring Emerging Non-Statin LDL Lowering Therapies
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Maya S. Safarova, MD, PhD, FNLA
Learn which patients with low-density lipoprotein (LDL) would benefit from this group of medication. In this episode, Dr. Alan Brown is joined by Dr. Maya Safarova, Chief Fellow in the Department of Cardiovascular Medicine at the University of Kansas Medical Center, to discuss the benefits of non-sta
Assessing the Effectiveness of Lp(a) Lowering Therapies in Clinical Trials
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host,
Stanford Surgeons Perform First Beating-Heart Procedure
Host: Javed Butler, MD
Guest: John W. MacArthur
With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about thi
Treating Tricuspid Valve Regurgitation With Novel Replacement Device
Host: Javed Butler, MD
Guest: Pedro A Villablanca Spinetto, MD
A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interve
Exploring the Use of AI to Detect HFpEF
Guest: Patricia A. Pellikka, M.D.
Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 a
Updates from ACC 2023: Examining Transcatheter Repair Study Data
Guest: Paul Sorajja, MD
TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.
Cardio-Oncology: Key Clinical Data from ACC.23
Guest: Ana Barac, MD, PhD
The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.
The Emerging Field of Cardio-Oncology: A Look at the Multidisciplinary Team
Host: Javed Butler, MD
Guest: Ana Barac, MD, PhD
Cardio-oncology is a novel field in cardiovascular medicine that has rapidly grown over the past few years. What kind of role does multidisciplinary care have in it? Dr. Javed Butler is joined by Dr. Ana Barac from the Inova Heart and Vascular Institute to take a look at where cardio-oncology is and where it could be headed.
The STELLAR Trial: Key Data on Sotatercept for PAH
Host: Marius M. Hoeper, MD
A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of t
A Look at Lipoprotein(a): Key Screening & Treatment Strategies
According to the CDC, patients with familial hypercholesterolemia or patients who show signs of coronary heart disease are at an increased chance of having heart attack, stroke, and aortic stenosis due to high levels of lipoprotein(a). So how can me manage lipoprotein(a) in our patients? To discuss this, Dr. Mary Katherine Cheeley is joined by fellow ReachMD host Dr. Alan Brown, who’s al
Anticipated Updates on Statin Intolerance at ACC 2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Kevin C. Maki, PhD, FNLA, CLS
At the American College of Cardiology's 72nd Annual Scientific Session & Expo, cardiologists will gather to explore the latest advancements in the field. Joining us to share what you can expect to learn about statin intolerance at their upcoming session are Dr. Mary Katherine Cheeley an
The Role of Implementation Science in Familial Hypercholesterolemia
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Laney K. Jones, PharmD, MPH
Patients with familial hypercholesterolemia (FH) are at an increased risk of developing coronary heart disease at a young age. So what’s on the horizon for using implementation science strategies in treating patients with FH? Learn more about implementation science as Dr. Mary Katherine Cheel
Updated Guidelines for Youth With Dyslipidemia
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Lauren Williams, MCN,RD,LD
Kids with dyslipidemia don’t have much different nutritional needs than other young kids their age. However, there are a few key things to be aware of. So how can clinicians meet families where they are to improve their diet? Dive into the unique needs of youth with dyslipidemia as Dr. Mary Ka
A Look into the Effectiveness of Dietary Supplements
Host: Matthew Sorrentino, MD
Guest: Luke Laffin, MD
Six commonly used supplements thought to improve patients’ cholesterol may be doing more harm than good. So what do we need to know about these supplements? To walk us through the results of the SPORT trial, Dr. Matthew Sorrentino is joined by Dr. Luke Laffin, Co-Director of the Center for Blood Pressure Disorders at the Clevela
Uncovering the Results of the DELIVER Trial
Host: Javed Butler, MD
Guest: Scott Solomon, MD
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, l
Exploring Novel Tools for PAH: Measuring Severity with a New Blood Test
Host: Matthew Sorrentino, MD
Guest: Michael A. Solomon, MD, MBA
Guest: Sean Agbor-Enoh, MD, PhD
Pulmonary arterial hypertension (PAH) is a rare, and even fatal, condition that can impair the chest and lungs. But could a new blood test help us better assess disease severity and survivability in patients with PAH? To dive deeper into this topic, Dr. Matthew Sorrentino is joined
Investigating the Link Between PCOS & CV Risk Factors During Delivery
Host: Hector O. Chapa, MD, FACOG
Guest: Erin Michos
Polycystic ovary syndrome (PCOS) affects approximately 5 to 13 percent of women in the general population. And although previous research has shown its link to cardiovascular (CV) risk factors later in life, a new study has revealed that PCOS can increase the risk of heart complications during delivery. So what do these findings
When Climate & Cardiology Overlap: How Climate Change Can Impact Heart Health
Host: Javed Butler, MD
Guest: Sameed Khatana, MD, MPH
As global temperatures continue to rise, experts are calling attention to the devastating effects this can have on human health. Cardiovascular mortality is especially a concern, as two recent studies from the University of Pennsylvania outlined the connection between these two health risks. To learn more about how climate cha
The miniPUMP: A New Way to Get a Close-Up View of the Heart
Host: Javed Butler, MD
Guest: Alice White, PhD
Guest: Christopher Chen, MD, PhD
There is currently no safe way to get a close-up view of the human heart, which is exactly why a team of Boston University researchers created a device to mimic the human organ. So how does the new device called miniPUMP work, and how was it developed? To discuss this, Dr. Javed Butler is joined b
Improving Adherence Among HF Patients: A Look at the PROMPT-HF Trial
Host: Javed Butler, MD
Guest: Tariq Ahmad, MD, MPH
The Pragmatic Trial of Messaging to Providers About Treatment in Heart Failure (PROMPT-HF) was designed to test the hypothesis that tailored and targeted electronic health record alerts recommending guideline-directed medical therapy (GDMT) for patients with heart failure (HF) would result in greater adherence to medication use.
What the SODIUM-HF Trial Means for Heart Failure Patients
Host: Javed Butler, MD
Guest: Justin Ezekowitz, MD, MBBCh, MSc
The Study of Dietary Intervention under 100 millimole in Heart Failure (SODIUM-HF) trial was designed to assess the effects of a low-sodium diet on adverse cardiovascular events. So what were the study’s findings, and what do they mean for our patients with heart failure? Dr. Javed Butler is joined by Dr. Justin Ezeko
Recommended
McKinsey on Consumer and Retail
megahired.com
Hard Knocks Podcast
Effective Weight Loss for Moms | High protein, Strength Training, Lose Weight, Meal Planning, Fat Loss, Healthy Habits
The Human-Animal Connection - Pet Life Radio Original
Infinite Health with Dr. Arasi Maran
The Daily
World News Tonight with David Muir
The Joe Rogan Experience
English Vocabulary Help
TED Talks Daily
Learn English B1 with Daily News | English Listening Practice
